Replies to post #210707 on Avid Bioservices Inc (CDMO)

[north40000]

I tend to agree the undervalued title might go to AMRN at the moment, but it is catching up fast. Interesting comparison between the 2---PPHM has to recover from the Fargo incident at the hands of its CRO employee[s], and AMRN must recover from the FDA adcom decision and the FDA rescinding, sua sponte, AMRN's SPA. At least AMRN's omega-3 capsule, Vascepa[96% EPA], is approved for a somewhat narrow indication, but can be prescribed off-label for others, accounting for the reason my physician prescribed it for me 2 years ago.

[md1225]

AMRN a good play no doubt but market potential for purified fish oil?????? Maybe Maybe 300M annually IF Lovaza was off the market.

Bavituximab WILL have sales of 2B annually!

All solid tumors.

Now Steve King mentions blood cancers? PCYC bought for 21B for one blood cancer drug???

Bavituximab value astronomical!